|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2018
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01EX10
|
|
gptkbp:blackBoxWarning
|
no
|
|
gptkbp:brand
|
gptkb:Vitrakvi
|
|
gptkbp:CASNumber
|
1223405-08-0
|
|
gptkbp:chemicalFormula
|
C21H22F2N6O2
|
|
gptkbp:developer
|
gptkb:Bayer
gptkb:Loxo_Oncology
|
|
gptkbp:drugClass
|
antineoplastic agent
|
|
gptkbp:eliminationHalfLife
|
2.9 hours
|
|
gptkbp:firstBook
|
yes
|
|
gptkbp:form
|
capsule
oral solution
|
|
gptkbp:genericName
|
gptkb:larotrectinib
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Vitrakvi
|
|
gptkbp:indication
|
gptkb:NTRK_fusion-positive_cancers
|
|
gptkbp:legalStatus
|
Rx-only
|
|
gptkbp:marketedIn
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
TRK inhibitor
|
|
gptkbp:metabolism
|
liver (CYP3A4)
|
|
gptkbp:molecularWeight
|
428.44 g/mol
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:proteinBinding
|
70%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
vomiting
dizziness
fatigue
increased liver enzymes
|
|
gptkbp:target
|
gptkb:NTRK_gene_fusion
|
|
gptkbp:usedFor
|
gptkb:cancer
solid tumors
|
|
gptkbp:bfsParent
|
gptkb:larotrectinib
gptkb:Larotrectinib
|
|
gptkbp:bfsLayer
|
7
|